Evidence map›Paper›PMID 37808200›Full record

ArticleIn vitro models2023

Application of a 3D hydrogel-based model to replace use of animals for passaging patient-derived xenografts.

Sal Jones, Jennifer C Ashworth, Marian Meakin, Pamela Collier, Catherine Probert, Alison A Ritchie, Catherine L R Merry, Anna M Grabowska

Abstract read
In one paragraph

Article in In vitro models, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed.

  1. Review
  2. Article
  3. Article
  4. Article
  5. The role of mesenchymal cells in cholangiocarcinoma.Disease models & mechanisms · 2024
    Article
  6. Review
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Sal JonesEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0003-2351-8622
Jennifer C AshworthEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0003-4189-8876
Marian MeakinEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Pamela CollierEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Catherine ProbertEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.
Alison A RitchieEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0002-5092-4979
Catherine L R MerryStem Cell Glycobiology Group, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0002-3490-2809
Anna M GrabowskaEx Vivo Cancer Pharmacology Centre, Translational Medical Sciences, School of Medicine, Biodiscovery Institute, University of Nottingham, Nottingham, UK.ORCID 0000-0003-1507-921X

Funding

National Centre for the Replacement, Refinement and Reduction of Animals in Research NC/N001583/1
6 · The paper itself

Abstract

Purpose: This 3D in vitro cancer model for propagation of patient-derived cells, using a synthetic self-assembling peptide gel, allows the formation of a fully characterised, tailorable tumour microenvironment. Unlike many existing 3D cancer models, the peptide gel is inert, apart from molecules and motifs deliberately added or produced by cells within the model. Methods: Breast cancer patient-derived xenografts (PDXs) were disaggregated and embedded in a peptide hydrogel. Growth was monitored by microscopic examination and at intervals, cells were extracted from the gels and passaged on into fresh gels. Passaged cells were assessed by qPCR and immunostaining techniques for the retention of characteristic markers. Results: Breast cancer PDXs were shown to be capable of expansion over four or more passages in the peptide gel. Contaminating mouse cells were found to be rapidly removed by successive passages. The resulting human cells were shown to be compatible with a range of common assays useful for assessing survival, growth and maintenance of heterogeneity. Conclusions: Based on these findings, the hydrogel has the potential to provide an effective and practical breast cancer model for the passage of PDXs which will have the added benefits of being relatively cheap, fully-defined and free from the use of animals or animal products. Encapsulated cells will require further validation to confirm the maintenance of cell heterogeneity, genotypes and phenotypes across passage, but with further development, including the addition of bespoke cell and matrix components of the tumour microenvironment, there is clear potential to model other cancer types. Supplementary Information: The online version contains supplementary material available at 10.1007/s44164-023-00048-x.

Indexed as

3D cultureBreast cancerHydrogelIn vitro modelPDXTumour microenvironment

Identifiers

PMID37808200
PMCPMC10550889

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.